Rosiglitazone effects on cardiovascular risk factors and ischemia

被引：0
|
作者：
Raji, A
Di Carli, M
Seidl, K
Stone, P
Plutzky, J
机构：
来源：
DIABETES | 2003年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A472 / A472
页数：1
相关论文
共 50 条
  • [41] The effects of oral vitamin supplementation on cardiovascular risk factors
    Woodside, JV
    Young, IS
    Yarnell, JWG
    McMaster, D
    Evans, AE
    PROCEEDINGS OF THE NUTRITION SOCIETY, 1997, 56 (1B) : 479 - 488
  • [42] Cardiovascular risk and cardiovascular risk factors in adolescents
    Chaves Rouberte, Emilia Soares
    de Araujo, Thelma Leite
    de Sousa, Daniel Freire
    Castro Nogueira, Daiany Maria
    Maia, Rebecca Silveira
    Moreira, Rafaella Pessoa
    Holanda de Sousa, Ederson Laurindo
    Bezerra Pinto, Livia Mara
    REVISTA BRASILEIRA DE ENFERMAGEM, 2022, 75 (04)
  • [43] Rosiglitazone in combination with metformin shows greater reductions in cardiovascular risk factors in patients who are highly insulin resistant
    Patwardhan, RN
    Lin, XW
    Stewart, MW
    DIABETES, 2004, 53 : A159 - A159
  • [44] Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone
    Monami, Matteo
    Marchionni, Niccolo
    Mannucci, Edoardo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 82 (01) : 48 - 57
  • [45] Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
    Simo, Rafael
    Rodriguez, Angel
    Caveda, Elena
    CURRENT DRUG SAFETY, 2010, 5 (03) : 234 - 244
  • [46] The cardiovascular safety of rosiglitazone
    Ajjan, Ramzi A.
    Grant, Peter J.
    EXPERT OPINION ON DRUG SAFETY, 2008, 7 (04) : 367 - 376
  • [47] The effects of exercise on cardiovascular disease risk factors and cardiovascular physiology in rheumatoid arthritis
    Metsios, George S.
    Moe, R. H.
    van der Esch, M.
    van Zanten, J. J. C. S. Veldhuijzen
    Fenton, S. A. M.
    Koutedakis, Y.
    Vitalis, P.
    Kennedy, N.
    Brodin, N.
    Bostrom, C.
    Swinnen, T. W.
    Tzika, K.
    Niedermann, K.
    Nikiphorou, E.
    Fragoulis, G. E.
    Vlieland, T. P. V. M.
    Van den Ende, C. H. M.
    Kitas, George D.
    RHEUMATOLOGY INTERNATIONAL, 2020, 40 (03) : 347 - 357
  • [48] The effects of exercise on cardiovascular disease risk factors and cardiovascular physiology in rheumatoid arthritis
    George S. Metsios
    R. H. Moe
    M. van der Esch
    J. J. C. S. Veldhuijzen van Zanten
    S. A. M. Fenton
    Y. Koutedakis
    P. Vitalis
    N. Kennedy
    N. Brodin
    C. Bostrom
    T. W. Swinnen
    K. Tzika
    K. Niedermann
    E. Nikiphorou
    G. E. Fragoulis
    T. P. V. M. Vlieland
    C. H. M. Van den Ende
    George D. Kitas
    Rheumatology International, 2020, 40 : 347 - 357
  • [49] Cardiovascular safety of rosiglitazone
    Krall, Ronald L.
    LANCET, 2007, 369 (9578): : 1995 - 1996
  • [50] What are the long-term cardiovascular effects of treatment with rosiglitazone?
    Fiby Nessim
    Lisel Loney-Hutchinson
    Samy I. McFarlane
    Current Diabetes Reports, 2008, 8 (3) : 201 - 202
12345